A joint press release from the companies indicates that BioNTech will obtain an initial payment of $1.5bn and will get yearly payments amounting to $2bn through the end of 2028. Moreover, the German firm can qualify for milestone payments totaling as much as $7.6bn once specific milestones are achieved.
The collaborators will equally divide the costs of development and production along with any profits (or losses).
Bristol Myers’ stock price has increased by 1 percent in Monday’s pre-market. The price of BioNTech’s ADR on the Nasdaq market surged almost 12%.
Since the start of 2025, Bristol Myers’ capitalization decreased by nearly 15% (to $95.3 billion), whereas the S&P 500 stock index increased by 0.5%.
source: bloomberg.com
